

# Wojciech Jurczak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3165702/publications.pdf>

Version: 2024-02-01

137  
papers

10,247  
citations

109321

35  
h-index

36028

97  
g-index

140  
all docs

140  
docs citations

140  
times ranked

8432  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 507-516.	27.0	1,449
2	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 768-778.	10.7	676
3	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 331-344.	27.0	564
4	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 229-240.	13.7	517
5	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2492-2499.	1.6	394
6	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. <i>Lancet</i> , The, 2020, 395, 1278-1291.	13.7	393
7	Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2016, 387, 770-778.	13.7	389
8	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1285-1295.	1.6	388
9	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i> , 2015, 126, 739-745.	1.4	349
10	Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , The, 2018, 391, 659-667.	13.7	324
11	Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 978-988.	10.7	320
12	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1433-1442.	10.7	306
13	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. <i>Blood</i> , 2020, 136, 2038-2050.	1.4	281
14	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 351-363.	27.0	278
15	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3441-3452.	1.6	266
16	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet</i> , The, 2021, 397, 892-901.	13.7	260
17	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	1.6	257
18	ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 2849-2861.	1.6	235

#	ARTICLE	IF	CITATIONS
19	Postibrutinib outcomes in patients with mantle cell lymphoma. <i>Blood</i> , 2016, 127, 1559-1563.	1.4	228
20	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 297-311.	10.7	219
21	Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. <i>Lancet Haematology</i> , the, 2019, 6, e67-e78.	4.6	146
22	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002); Tj ETQq0 0 0 rgBT /Overlock 10 Tf	10.7	135
23	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	1.6	132
24	Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. <i>British Journal of Haematology</i> , 2018, 183, 479-490.	2.5	131
25	Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent <i>CARD11</i> mutations. <i>Oncotarget</i> , 2016, 7, 38180-38190.	1.8	130
26	Umbralisib, a Dual PI3K $\beta$ /CK1 $\mu$ Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1609-1618.	1.6	111
27	Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2405-2412.	1.6	81
28	Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2417-2426.	3.5	81
29	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1171-1175.	7.2	72
30	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. <i>Lancet Haematology</i> , the, 2017, 4, e362-e373.	4.6	70
31	Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. <i>Lancet Haematology</i> , the, 2017, 4, e350-e361.	4.6	69
32	Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 791-799.	2.3	53
33	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. <i>Lancet Haematology</i> , the, 2018, 5, e543-e553.	4.6	53
34	ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 31-31.	1.4	47
35	Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. <i>Blood Advances</i> , 2022, 6, 1296-1308.	5.2	42
36	Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen – A national multicenter study. <i>International Journal of Cardiology</i> , 2013, 168, 5212-5217.	1.7	41

#	ARTICLE	IF	CITATIONS
37	Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 4091-4101.	5.2	33
38	Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 179.	17.0	33
39	Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice – Report of a European workshop. <i>European Journal of Cancer</i> , 2008, 44, 366-373.	2.8	25
40	Outcomes of treatment with dose-adjusted EPOCH or R-CHOP in primary mediastinal large B-cell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 59-66.	2.2	25
41	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. <i>Leukemia</i> , 2021, 35, 3201-3211.	7.2	25
42	Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 455-463.	3.1	24
43	The effect of tensile stresses on aluminium passive layer durability. <i>Electrochimica Acta</i> , 2006, 51, 6091-6096.	5.2	21
44	Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference. <i>Leukemia and Lymphoma</i> , 2010, 51, 1612-1622.	1.3	21
45	The effect of strain rate on the passive layer cracking of 304L stainless steel in chloride solutions based on the differential analysis of electrochemical parameters obtained by means of DEIS. <i>Journal of Electroanalytical Chemistry</i> , 2005, 576, 277-285.	3.8	20
46	Comparative Electrochemical Analysis of the Passive Layer Cracking Process on Aluminum Alloys Performed by Means of DC and AC Techniques. <i>Journal of the Electrochemical Society</i> , 2007, 154, C74.	2.9	20
47	Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. <i>British Journal of Haematology</i> , 2018, 183, 400-410.	2.5	18
48	Passive Layer Cracking Studies Performed on A95056 Aluminum Alloy by DEIS and Acoustic Emission. <i>Electrochemical and Solid-State Letters</i> , 2005, 8, B55.	2.2	17
49	Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen. <i>Chemotherapy</i> , 2018, 63, 238-245.	1.6	17
50	Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. <i>Leukemia and Lymphoma</i> , 2019, 60, 1610-1625.	1.3	16
51	First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. <i>British Journal of Haematology</i> , 2020, 188, 898-906.	2.5	16
52	Surface Finish Analysis in Single Point Incremental Sheet Forming of Rib-Stiffened 2024-T3 and 7075-T6 Alclad Aluminium Alloy Panels. <i>Materials</i> , 2021, 14, 1640.	2.9	16
53	Corrosion of ammunition dumped in the Baltic Sea. <i>Journal of KONBiN</i> , 2017, 41, 227-246.	0.4	16
54	Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. <i>Leukemia and Lymphoma</i> , 2017, 58, 2824-2832.	1.3	15

#	ARTICLE	IF	CITATIONS
55	The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients. <i>Cancer Medicine</i> , 2019, 8, 1103-1109.	2.8	15
56	Quadratic Cohen representations in spectral analysis of serration process in Al-Mg alloys. <i>Computational Materials Science</i> , 2007, 39, 880-886.	3.0	14
57	Rituximab biosimilars for lymphoma in Europe. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1045-1056.	3.1	13
58	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation. <i>Translational Oncology</i> , 2021, 14, 100977.	3.7	13
59	Integrated safety analysis of umbralisib, a dual PI3K/CK1 $\mu$ inhibitor, in relapsed/refractory lymphoid malignancies. <i>Blood Advances</i> , 2021, 5, 5332-5343.	5.2	13
60	Avatrombopag for the treatment of immune thrombocytopenia. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 327-339.	3.0	12
61	Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP – the PLRG report. <i>Scientific Reports</i> , 2020, 10, 3517.	3.3	12
62	Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 224-235.	2.5	10
63	Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma. <i>American Journal of Therapeutics</i> , 2016, 23, e749-e756.	0.9	9
64	Use of acalabrutinib in patients with mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2018, 11, 495-502.	2.2	9
65	Acalabrutinib for adults with mantle cell lymphoma. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 179-187.	3.1	9
66	Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers. <i>Medical Oncology</i> , 2015, 32, 90.	2.5	8
67	Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 123.	0.8	8
68	Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders. <i>International Journal of Cardiology</i> , 2017, 235, 147-153.	1.7	8
69	Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 670-678.	1.3	8
70	Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases. <i>Future Oncology</i> , 2019, 15, 4223-4234.	2.4	8
71	Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study. <i>Anticancer Research</i> , 2020, 40, 4059-4066.	1.1	8
72	Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis. <i>Advances in Therapy</i> , 2021, 38, 3113-3128.	2.9	8

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities – Polish Adult Leukemia Group (PALG) real-life analysis. Polish Archives of Internal Medicine, 2018, 128, 421-426.	0.4	8
74	Prediction of Welding-Induced Distortion of Fixed Plate Edge Using Design of Experiment Approach. Polish Maritime Research, 2020, 27, 134-142.	1.9	7
75	Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL Study. Wspolczesna Onkologia, 2015, 3, 214-219.	1.4	6
76	Microstructure, Mechanical Properties, and Corrosion Resistance of Thermomechanically Processed AlZn6Mg0.8Zr Alloy. Materials, 2018, 11, 570.	2.9	6
77	Microstructural and Fractographic Analysis of Plastically Deformed Al-Zn-Mg Alloy Subjected to Combined High-Cycle Bending-Torsion Fatigue. Metals, 2018, 8, 487.	2.3	6
78	Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group*. Leukemia and Lymphoma, 2019, 60, 341-348.	1.3	6
79	Consolidation with <sup>90</sup> Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up. Leukemia and Lymphoma, 2019, 60, 2689-2696.	1.3	6
80	Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 89-97.	0.4	6
81	Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. Leukemia and Lymphoma, 2021, 62, 3440-3451.	1.3	6
82	Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. Blood Advances, 2021, 5, 3354-3361.	5.2	6
83	Study of the Corrosion Resistance of Ship Aluminium Alloys. Scientific Journal of Polish Naval Academy, 2016, 206, 37-65.	0.2	6
84	Central nervous system prophylaxis with intrathecal liposomal cytarabine in diffuse large B-cell lymphomas. Polish Archives of Internal Medicine, 2013, 123, 589-595.	0.4	6
85	Corrosion Influence on Safety of Hydraulic Pipelines Installed on Decks of Contemporary Product and Chemical Tankers. Polish Maritime Research, 2018, 25, 71-77.	1.9	6
86	Dynamic properties of 7000 - series aluminum alloys at large strain rates. Polish Maritime Research, 2012, 19, .	1.9	5
87	Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. Health and Quality of Life Outcomes, 2019, 17, 173.	2.4	5
88	The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions. Future Oncology, 2019, 15, 305-317.	2.4	5
89	The Rapeseed Oil Based Organofunctional Silane for Stainless Steel Protective Coatings. Materials, 2020, 13, 2212.	2.9	5
90	Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry. Annals of Hematology, 2020, 99, 1073-1079.	1.8	5

#	ARTICLE	IF	CITATIONS
91	Gemcitabine-Based Treatment in Poor Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma – a Multicenter Polish Experience. <i>Advances in Clinical and Experimental Medicine</i> , 2015, 24, 783-789.	1.4	5
92	Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 741-748.	0.4	5
93	The effect of heat treatment on the structure and corrosion resistance of Al-Zn-Mg alloys. <i>Polish Maritime Research</i> , 2008, 15, 66-71.	1.9	4
94	A Twelve-Year Follow-Up Study on a Case of Early-Onset Parkinsonism Preceding Clinical Manifestation of Gaucher Disease. <i>JIMD Reports</i> , 2011, 3, 53-57.	1.5	4
95	Damage and Corrosion Diagnostics of Welded Light Alloys Ship Constructions. <i>Solid State Phenomena</i> , 0, 196, 20-27.	0.3	4
96	Impact and Ballistic Resistance of a New Aluminium Alloy for Ship Construction Elements. <i>Polish Maritime Research</i> , 2015, 22, 72-78.	1.9	4
97	Design Methodology of Strength Verification of Platform During Load Out of the Arkutun Dagi SE-Topside 43.800 MT. <i>Polish Maritime Research</i> , 2016, 23, 117-128.	1.9	4
98	Effect of Frictional-Mechanical Treatment of the Low Alloy Steels on Some Exploitation Properties in Sea Water Simulated Solution. <i>Solid State Phenomena</i> , 0, 250, 56-60.	0.3	3
99	Influence of Friction Stir Welding (FSW) on Mechanical and Corrosion Properties of AW-7020M and Aw-7020 Alloys. <i>Polish Maritime Research</i> , 2016, 23, 86-90.	1.9	3
100	Is Good Clinical Practice Becoming Poor Clinical Care?. <i>HemaSphere</i> , 2017, 1, e4.	2.7	3
101	Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma – Polish Lymphoma Research Group real-life analysis. <i>Pharmacological Reports</i> , 2019, 71, 473-477.	3.3	3
102	Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1066-1076.	1.3	3
103	Influence of Hydrostatic Extrusion on the Mechanical Properties of the Model Al-Mg Alloys. <i>Journal of Materials Engineering and Performance</i> , 2021, 30, 3502-3509.	2.5	3
104	Modelling of the Ship Structural Ballistic Shields from the 10GHMBA Steel. <i>Solid State Phenomena</i> , 2011, 180, 303-312.	0.3	2
105	Simulating the Impact of Exposure to Corrosive Medium on Cracking Initiation in AW7020M Alloy Specimens. <i>Solid State Phenomena</i> , 0, 210, 130-135.	0.3	2
106	Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 325.	0.8	2
107	The use of Yttrium-90 Ibritumomab Tiuxetan ( 90 Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation. <i>Wspolczesna Onkologia</i> , 2015, 1, 43-47.	1.4	2
108	Primary mediastinal B-cell lymphoma – metabolic and anatomical features in 18FDG-PET/CT and response to therapy. <i>Wspolczesna Onkologia</i> , 2016, 4, 297-301.	1.4	2

#	ARTICLE	IF	CITATIONS
109	The influence of Mg addition and hydrostatic extrusion HE on the repassivation ability of pure Al, AlMg1 and AlMg3 model alloys in 3.5 wt-% NaCl. <i>Corrosion Engineering Science and Technology</i> , 2019, 54, 666-672.	1.4	2
110	Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00649.	2.4	2
111	Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors. <i>Advances in Medical Sciences</i> , 2020, 65, 371-377.	2.1	2
112	Static and Dynamic Properties of Al-Mg Alloys Subjected to Hydrostatic Extrusion. <i>Materials</i> , 2022, 15, 1066.	2.9	2
113	Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórkami pŁaszcza – wyniki miŁdzynarodowego, wielooŁrodkowego, badania II fazy z ibrutynibem (PCI-32765) – EHA.3 Encore. <i>Acta Haematologica Polonica</i> , 2013, 44, 314-318.		1
114	Research on Biosimilars: pivotal trials and principles. <i>Lancet Haematology</i> , 2017, 4, e409-e410.	4.6	1
115	Rytuksymab – pierwsze biopodobne przeciwciaŁa monoklonalne w hematologii. <i>Acta Haematologica Polonica</i> , 2017, 48, 269-273.	0.3	1
116	Helping the cardio-oncologist: from real life to guidelines. <i>Seminars in Oncology</i> , 2019, 46, 433-436.	2.2	1
117	Cardio-oncology for better lymphoma therapy outcomes. <i>Lancet Haematology</i> , 2020, 7, e273-e275.	4.6	1
118	Rituximab biosimilars in clinical practice. <i>Leukemia and Lymphoma</i> , 2020, 61, 1523-1524.	1.3	1
119	Phase I, first-in-human trial of Bruton’s tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	1.3	1
120	MICROSCOPIC EXAMINATION OF AlZn5Mg1 ALLOY JOINTS WELDED BY FSW AND MIG. <i>Journal of KONES</i> , 2015, 19, 129-135.	0.2	1
121	Nivolumab for relapsed/refractory classical Hodgkin lymphoma after brentuximab vedotin failure – Polish Lymphoma Research Group real-life experience. <i>Acta Haematologica Polonica</i> , 2018, 49, 228-233.	0.3	1
122	The necessity of post-induction therapy in mantle cell lymphoma patients: A multicenter retrospective real-world analysis by Polish Lymphoma Research Group (PLRG). <i>Postepy Higieny i Medycyny Doswiadczalnej</i> , 2019, 73, 303-309.	0.1	1
123	EFFECT OF HUMIDITY ON TRIBOLOGICAL PROPERTIES OF SELECTED FRICTION JUNCTIONS WITH AN EVALUATION OF ACOUSTIC EMISSION. <i>Tribologia</i> , 2021, 297, 9-18.	0.2	1
124	Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results. <i>Medical Oncology</i> , 2012, 29, 2070-2076.	2.5	0
125	Exploitation Load Impact on Electrochemical Properties of Shipbuilding 7xxx Series Aluminum Alloy Joints Prepared with TIG and FSW Methods. <i>Solid State Phenomena</i> , 2021, 0, 236, 53-61.	0.3	0
126	Treatment of high-risk follicular lymphoma. <i>HemaSphere</i> , 2019, 3, 85-87.	2.7	0



#	ARTICLE	IF	CITATIONS
127	Submarine Resistance Force Characteristics Determination after Modification of Depth Rudder System. <i>Advances in Science and Technology Research Journal</i> , 2021, 15, 1-9.	0.8	0
128	The Exploitation Problems Marine Light Constructions for Corrosion Resistance / Problemy Eksploatacyjne Lekkich Konstrukcji Morskich w Aspekcie Odporności Korozyjnej. <i>Journal of KONBiN</i> , 2015, 33, 5-18.	0.4	0
129	Impact Resistance of Aluminium Ship Structures. <i>Scientific Journal of Polish Naval Academy</i> , 2016, 207, 45-54.	0.2	0
130	Possibilities of Belzona Adhesive Joints Application for Austenitic Steel Used in Ship Constructions. <i>Advances in Science and Technology Research Journal</i> , 2017, 11, 134-140.	0.8	0
131	Ocena profilu korzyści i ryzyka leczenia idelalizybem u chorych na przewlekłą... białaczkę limfocytową i chłoniaki nie-Hodgkina. <i>Hematologia</i> , 0, , .	0.0	0
132	Early chemotherapy de-escalation strategy in advanced-stage Hodgkin lymphoma patients with negative positron emission tomography scan after two escalated BEACOPP cycles. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 259-266.	0.4	0
133	Stosowanie leków biopodobnych w hematologii – stanowisko Polskiego Towarzystwa Hematologów i Transfuzjologów. <i>Acta Haematologica Polonica</i> , 2019, 50, 51-56.	0.3	0
134	Chłoniak z komórek plazmacyt – rola terapii celowanych. <i>Acta Haematologica Polonica</i> , 2019, 50, 116-120.	0.3	0
135	Passive Corrosion Protection of Al-Zn-Mg alloy in Seawater. <i>Nase More</i> , 2019, 66, 103-111.	0.5	0
136	Mechanical Properties of Welded Joints of 1.3964 Steel for Computer Aided Engineering (CAE) Purposes. <i>Scientific Journal of Polish Naval Academy</i> , 2020, 220-221, 15-28.	0.2	0
137	The Analysis of the Strength of the Ship's Hull After Running Aground. , 2022, 224, 16-27.		0